Cutaneous Paraneoplastic Syndroma of Breast Cancer: About 2 Cases

Hadidane Manel¹, Slimane M², Chemlali Molka³, Henchiri Houda¹, Ben Hassouna Jame³, Rahal Khaled²

Oncology Surgical Departement, Salah Azaiz Institute, Tunis, Tunisia

Abstract: Paraneoplastic syndroma are rare disorders that are triggered by an altered immune system response to a neoplasm. They are defined as clinical syndromes involving nonmetastatic systemic effects that accompany malignant disease. Paraneoplastic dermatoses are heterogeneous group of clinical manifestations that often appear benign. They represent the 2nd most common paraneoplastic site (the 1st endocrine syndromes). They commonly precede or follow visceral cancer. Recognition may result in earlier diagnosis and better prognosis. We report two cases of paraneoplastic dermatosis that are rarely associated with breast cancer.

Keywords: cutaneous, paraneoplastic, syndroma, breast, cancer

1. Introduction

Paraneoplastic syndroma are rare disorders that are triggered by an altered immune system response to a neoplasm. They are defined as clinical syndromes involving nonmetastatic systemic effects that accompany malignant disease [1-2-3]. Paraneoplastic syndroma arise from tumor secretion of hormones, peptides, cytokines or from immune cross-reactivity between malignant and normal tissues. They may affect diverse organ systems, most notably the endocrine, neurologic, dermatologic, rheumatologic, and hematoologic systems. It is estimated that paraneoplastic syndromes affect up to 8% of patients with cancer. The most commonly associated malignancies include small cell lung cancer, breast cancer, gynecologic tumors, and hematologic malignancies. Paraneoplastic dermatoses are a heterogeneous group of clinical manifestations that often appear benign. They represent the 2nd most common paraneoplastic site (the 1st endocrine syndromes). They commonly precede or follow visceral cancer. Recognition may result in earlier diagnosis and better prognosis. In fact the skin may exhibit the first clinical evidence of a systemic disease and may provide the first clues to a diagnosis in up to 1% of internal malignancies [4]. Since cutaneous paraneoplastic syndromes commonly precede or follow visceral cancer, their recognition may result in earlier diagnosis and better prognosis for the patient [5-6]. Breast cancer is associated with paraneoplastic manifestations from many systems. The most common skin paraneoplastic manifestations of breast cancer are acanthosis nigricans, erythromelalgia, thrombotic thrombocytopenic purpura, acrokeratosis paraneoplastica, paraneoplastic hypertrichosis lanuginosa acquisita, dermatomyositis, systemic sclerosis, and scleroderma [7-8]. We present here two cases of cutaneous paraneoplastic syndroma that are rarely associated with breast cancer.

2. Case 1:

First case is a 61-year-old woman, with history of hypertension. She consulted for a squamous nipple lesion of the left breast evolving since three months. The clinical breast examination revealed a squamous lesion in the left nipple evoking Paget disease (Figure 1)
mass, an enlarged ulcerative painful cutaneous lesion, with purple and undermined edge situated on the anterior surface of both legs that evolving rapidly since 1 month (Figure 3). The cutaneous presentation was typically correlated with pyoderma gangrenosum. The patient received anti-inflammatory and anti staphylococcus therapy for two weeks without success inherit cutaneous disease. The abdominal mass was explored by MRI (magnetic resonance imaging) showing a well-limited abdomino pelvic mass measuring 20x15x12 cm, surrounded by a thick wall. The mass was a heterogenous hypo intense in T1 and T2, with necrosis area. The CA 15-3 (>200 U/ml) and CA 125 (carbohydrate antigen) (<600U/ml) level were pathologic with normal level of CA 19-9. Then she undergone a laparotomy with right adnexectomy of an ovarian suspicious mass. The cutaneous lesions had been remarkably improved after the resection of ovarian metastasis and within chemotherapy for metastatic disease. Currently, the patient is still receiving chemotherapy with good resolution of her cutaneous lesion.

4. Discussion

In the clinical setting, the paraneoplastic manifestation may precede the diagnosis of the related neoplasm, often by months or years.

In some instances, the timely diagnosis of these conditions may lead to detection of an otherwise clinically occult tumor at an early and highly treatable stage.

In other cases, confirmation of the association may require a statistical approach.

In general, the skin may be directly or indirectly involved in malignancies. Indirect involvement, as in paraneoplastic dermatosis, is caused by a variety of factors (inflammatory, proliferative or metabolic factors) related to the neoplasia, such as polypeptides, hormones, cytokines, antibodies or growth factors that act as mediators, interfering with cell communication and, consequently, with its activity. In this case, there is no presence of neoplastic cells in the skin, and this involvement is considered a dermatological paraneoplastic syndrome [9-10].

Moreover, cutaneous paraneoplastic syndromes are important clinical markers that may also precede (most commonly), occur simultaneously or after the diagnosis of a given neoplasm. More than 50 dermatoses have been correlated with underlying neoplastic processes.

The presence of cutaneous paraneoplastic syndrome is often associated with a poor prognosis.

Cutaneous paraneoplastic changes may be an important clue to the presence of an otherwise asymptomatic malignancy. Indeed, in over one third of patients, complaints related to the paraneoplastic condition precede the diagnosis of the malignancy by months or years. Sometimes, they may also be suggestive of the specific type of cancer present. The clinician must be aware of these dermatosis to rule out a potential cancer underlying or simple benign manifestation of a systemic disease.

In general, since paraneoplastic syndromes are caused by the tumor, the cancer must precede the development of the dermatosis and the two conditions should follow a parallel course [11]. In the first case of our report, the paraneoplastic Raynaud’s phenomenon appeared simultaneously with the breast cancer diagnosis and had parallel progression.

However, in the second case, the paraneoplastic dermatosis onset with the breast metastatic recurrence. Thereby, paraneoplastic syndromes may be the first indication of a new or recurrent tumor and failure to recognize their import may have significant consequence.

Raynaud’s phenomenon associated with malignancies is a rarely reported clinical entity. An important review identified only 33 cases of paraneoplastic Raynaud’s syndrome in the medical literature [12]. The underlying malignancies among patients with paraneoplastic Raynaud’s phenomenon can be highly varied, including carcinomas of the lung, breast, ovary, testes, skin and thyroid. Sarcomas and haematological malignancies too have been associated [13-14]. The first case of secondary Raynaud’s phenomenon associated with breast cancer in the absence of an underlying rheumatic condition was reported by David Allen in 2010 [15].

Pyoderma gangrenosum is a rare clinical entity of poorly understood pathogenesis, characterized by rapidly progressing skin necrosis. In around half of cases, pyoderma gangrenosum is associated with various underlying specific conditions, most frequently rheumatoid arthritis, inflammatory bowel disease or myeloproliferative disorders. There have been few reports on the association of pyoderma gangrenosum with solid malignancies including breast cancer [16-17]. Additionally, a few cases of pyoderma gangrenosum of the breast precipitated by breast surgery were reported [16-18]. The most common location of pyoderma gangrenosum is the legs but the disease may also involve other regions, particularly at the site of even minor trauma or surgery [18]. One case report of recurrent pyoderma gangrenosum that was precipitated by breast cancer was published in 2014 by Rinata Duchnowska [19].

Because of their protean manifestations, paraneoplastic syndromes should be managed by a coordinated team of physicians, including medical oncologists, surgeons, radiation oncologists, endocrinologists, hematologists, neurologists, and dermatologists.

Since they often cause considerable morbidity, effective treatment of paraneoplastic dermatosis can improve patient quality of life, enhance the delivery of cancer therapy, and prolong survival. Treatments include addressing the underlying malignancy, immunosuppression (for neurologic, dermatologic, and rheumatologic paraneoplastic syndromes), and correction of electrolyte and hormonal derangements (for endocrine paraneoplastic syndromes).

Most of paraneoplastic dermatoses disappear when the primary tumour is removed and reappear in the case of recurrence or metastases of the cancer. Due to association
with serious underlying conditions, rapid development and potentially serious consequences, Raynaud’s phenomenon and pyoderma gangrenosum necessitates especially prompt and thorough diagnosis, including the search for coexisting disease.

5. Conclusion

Early recognition of these cutaneous hallmarks offers an opportunity for early diagnosis, treatment of the internal malignancy and monitoring for tumor recurrence.

A sudden onset of any dermatosis should raise suspicions of its character being paraneoplastic.

Paraneoplastic dermatosis if not addressed can adversely affect quality of life.

Like all other paraneoplastic symptomatology, paraneoplastic dermatosis can be expected to abate after treatment against the underlying malignancy is initiated. In addition to eradication of the underlying malignancy, treatment of these syndroma may acquire immunotherapy and anti inflammatory therapy. A regular follow up of both underlying malignancy and associated paraneoplastic dermatosis is mandatory to make the diagnosis of a potential recurrence in time for an adequate treatment.

6. Acknowledgments

Written consent for publication was obtained from the patient.

7. Conflict of Interest Statement

The authors have no competing interests.

References

[1] Lancaster E. Paraneoplastic disorders. Continuum (Minneap Minn). 2015 Apr. 21 (2 Neuro-oncology):452-75.
[2] Gultekin SH. Recent developments in paraneoplastic disorders of the nervous system. Surg Pathol Clin. 2015 Mar. 8 (1):89-99.
[3] Bilynsky BT, Dzhus MB, Litvinyak RI. The conceptual and clinical problems of paraneoplastic syndrome in oncology and internal medicine. Exp Oncol. 2015 Jun. 37 (2):82-8
[4] Yuste Chaves M, Unamuno Pérez P. Cutaneous manifestations of systemic malignancies. Part 2. Actas Dermo-Sifiliograficas. 2013;104(7):543–553.
[5] Azulay RD, Azulay DR, Abulafia LA. Sinais malignos na pele versus síndromes paraneoplásicas cutâneas: revisão. An Bras Dermatol. 2000;75:621-30.
[6] Dourmishev LA, Draganov PV. Paraneoplastic dermatological manifestation of gastrointestinal malignancies. World J Gastroenterol. 2009;15:4372-9.
[7] Abreu Velez AM, Howard MS. Diagnosis and treatment of cutaneous paraneoplastic disorders. Dermatologic Therapy. 2010;23(6):662–675
[8] Da Silva JA, Igreja ACDSM, Freitas AF, et al. Paraneoplastic cutaneous manifestations: concepts and updates. Anais Brasileiros de Dermatologia. 2013;88(1):9–22.
[9] Ortega-Loayza AG, Ramos W, Gutierrez EL, Paz PC, Bobbio L, Galarza C. Cutaneous manifestations of internal malignancies in a tertiary health care hospital of a developing country. An Bras Dermatol. 2010;85:736-42.
[10] Thiers BH, Sahn RE, Callen JP. Cutaneous manifestations of internal malignancy. CA Cancer J Clin. 2009;59:73-98.
[11] Cohen PR. Cutaneous paraneoplastic syndromes. Am FAM Physician. 1994 Nov 1;50(6):1273-82
[12] Poszepczynska-Guigné, E., Viguier, M., Chosidow, O. et al. Paraneoplastic acral vascular syndrome: epidemiologic features, clinical manifestations, and disease sequelae. J Am Acad Dermatol. 2002;47:47–52.
[13] Domz CA, Chapman CG. Pseudo-Raynaud’s: cryoglobulinemia secondary to occult neoplasm. Calif Med 1961;95:391–3
[14] Auboire L, Landy S, Perrot JY, et al. [A negative first-line work-up of Raynaud’s phenomenon: And what if it were cancer?]. J Mal Vasc 2010;35:35–7.
[15] 15-Paraneoplastic Raynaud’s phenomenon in a breast cancer survivor. David Allen · David Robinson · Shikha Mittoo Rheumatol Int (2010) 30:789–792
[16] Kanno T, Ito M, Tsuji H, Kawase N, Taki Y: A case of pyoderma gangrenosum involving the prostate gland after radiation therapy for prostate cancer. Hinyokika Kiyo 2002, 48:565 568.
[17] Davis MD, Alexander JL, Prawer SE: Pyoderma gangrenosum of the breast precipitated by breast surgery. J Am Acad Dermatol 2006, 55:317–320. 12.
[18] Horner B, El-Muttardi N, Mercer D: Pyoderma gangrenosum complicating bilateral breast reduction. Br J Plast Surg 2004, 57:679–681.
[19] Recurrent pyoderma gangrenosum precipitated by breast cancer: a case report and review of the literature. Renata Duchnowska, Ewa Ziajka,Agnieszka Górala,and Bartlomiej Grała. J Med Case Rep. 2014; 8: 226.

Figure 1: Squamous lesion of the left nipple
Figure 2: Necrosis of fingertips

Figure 3: Ulceration of the anterior surface of both legs